Sarepta Therapeutics to Share Scientific Replace for SRP-5051, its Investigational PPMO for the Therapy of Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the chief in precision genetic medication for uncommon ailments, right this moment introduced that on Monday, Dec. 7, 2020 at 8:30 am Jap Time (ET), it can host a webcast and convention name to current interim knowledge from the MOMENTUM examine, a multiple-ascending dose scientific trial of SRP-5051 for the therapy of Duchenne muscular dystrophy. SRP-5051 is the primary investigational therapy utilizing Sarepta’s next-generation PPMO platform, which is designed round a proprietary cell-penetrating peptide conjugated to Sarepta’s phosphorodiamidate morpholino oligomer (PMO) spine with the aim of accelerating drug focus in muscle tissue.
The presentation will probably be webcast dwell below the investor relations part of Sarepta’s web site at https://investorrelations.sarepta.com/events-presentations and slides will probably be archived there following the decision for one 12 months. Please connect with Sarepta’s web site a number of minutes previous to the beginning of the printed to make sure satisfactory time for any software program obtain which may be obligatory. The convention name could also be accessed by dialing (844) 534-7313 for home callers and (574) 990-1451 for worldwide callers. The passcode for the decision is 6382259. Please specify to the operator that you simply wish to be part of the “Sarepta-hosted Scientific Replace for MOMENTUM name.”
About Sarepta Therapeutics
At Sarepta, we’re main a revolution in precision genetic medication and each day is a chance to alter the lives of individuals residing with uncommon illness. The Firm has constructed a formidable place in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis sort IIIA, Charcot-Marie-Tooth (CMT), and different CNS-related issues, with greater than 40 applications in numerous phases of improvement. The Firm’s applications and analysis focus span a number of therapeutic modalities, together with RNA, gene remedy and gene enhancing. For extra data, please go to www.sarepta.com or comply with us on Twitter, LinkedIn, Instagram and Facebook.
Web Posting of Info
We routinely put up data which may be necessary to buyers within the ‘Traders’ part of our web site at www.sarepta.com. We encourage buyers and potential buyers to seek the advice of our web site usually for necessary details about us.
Supply: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Traders:
Ian Estepan, 617-274-4052, iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com